CoChat
Sign Up
Cited by 18Renal Diseases and GlomerulopathiesChronic Kidney Disease and DiabetesLipid metabolism and disorders

Role of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses

Saito, T., Ishigaki, Y., Oikawa, S., Yamamoto, T. T.·2001·Clinical and Experimental Nephrology
DOI 10.1007/s10157-001-8014-3
Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1007/s10157-001-8014-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most LPG patients have been reported to present elevated plasma apoE levels, while normalization or reduction of apoE levels following various treatments results in remission or improvement of the disease.

    “Most of the LPG patients have been reported to present elevated plasma apoE levels (5, 6, 23-25), while it has been observed that normalization or reduction of apoE levels following various treatments (e.g., lipid-lowering treatments with fenofibrate or protein A immunoadsorption) result in remission or improvement of the disease (24,25,47).”

    From Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy (2018) · cites this paper as [23]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Saito, T., Ishigaki, Y., Oikawa, S., & Yamamoto, T. T.
Affiliations
  • Fukuoka University (JP)
  • Tohoku University (JP)
  • Nippon Medical School (JP)
ORCID
Venue
Clinical and Experimental Nephrology
Publisher
Springer Science and Business Media LLC
Published
2001-12-01
Volume
5
Issue
4
Pages
201-208
ISSN
  • 1342-1751 (ISSN-L)
  • 1437-7799
DOI
10.1007/s10157-001-8014-3
OpenAlex
W2051916158
Cited by
18
References
3
Citations by year
2021: 1 · 2018: 1 · 2016: 2 · 2013: 1
FWCI
0.48
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
Clinical and Experimental Nephrology (publishedVersion)
Topics
  • Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
lipoprotein glomerulopathy, apolipoprotein E, APOE2, type III hyperlipoproteinemia, diabetic nephropathy, IgA nephropathy, ApoE-deficient mice, adenoviral gene transfer, pathogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review